| Previous Close | 134.67 |
| Open | 134.49 |
| Bid | 0.00 x |
| Ask | 0.00 x |
| Day's Range | 130.11 - 135.23 |
| 52 Week Range | 75.52 - 153.15 |
| Volume | 1,193,071 |
| Avg. Volume | 2,022,071 |
| Market Cap | 26.68B |
| Beta | 1.83 |
| PE Ratio (TTM) | -231.46 |
| EPS (TTM) | -0.56 |
| Earnings Date | Aug 7, 2017 - Aug 11, 2017 |
| Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 147.00 |
- Thomson Reuters StreetEvents•12 hours ago
Edited Transcript of INCY earnings conference call or presentation 4-May-17 2:00pm GMT
Q1 2017 Incyte Corp Earnings Call
- Barrons.com•yesterday
Seattle Genetics: A Disappointing Study…Or Was It?
Shares of Seattle Genetics (SGEN) are moving lower today, falling more than 9% after the drug maker’s experimental lymphoma drug failed to impress. The data from the late-stage study testing Adcetris, co-developed with Japan's Takeda Pharmaceutical, helped blood cancer patients live longer without worsening their conditions, meeting its endpoint. Altogether, lots of uncertainty whether these data could support a robust commercial adoption.
- Investopedia•2 days ago
The Reason for the Big Rise in Biotech Stocks
Biotech shares have surged during the week of June 19.